This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

RG7795

Roche Holding AG

Drug Names(s): ANA773, RO6864018, RO-6864018

Description: RG7795 is an investigational oral small-molecule compound that acts via the Toll-like receptor 7 (TLR7) pathway in hepatitis. TLR7 agonists cause the production of antiviral cytokines and the activation/maturation of immune cells with the potential to enhance immune response.

Preclinical data show that the active metabolite of ANA773 promotes natural killer (NK) cell-mediated anti-tumor response by inducing cytokine secretion, cytolysis of tumor cells and enhanced antibody-dependent cellular cytotoxicity (ADCC).

Deal Structure: In October 2011, Anadys announced that it has entered into a definitive merger agreement to be acquired by Roche. Under the terms of the merger agreement, Roche will commence an all cash tender offer for all outstanding shares of common stock of Anadys at USD 3.70 per share. This corresponds to a total cash consideration of approximately USD 230 million. In November 2011, the acquisition was completed.


RG7795 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug